BETA-LACTAMASE
INHIBITORS
DR RAVI KUMAR S
PEDIATRIC RESIDENT
MGMCRI
BETA-LACTAM
Antibiotics which contain beta lactam ringsin theirmolecular
structuresare :
• Penicillin
• Cephalosporins
• Monobactum
• Carbapenem
MOA
• It interfereswith bacterial cell wall synthesis
• It inhibitsthe transpeptidases so that cross linkingdoes not take place
• Cross linkages between peptide chains of the neighbouringstrands
provides stabilityand rigiditytothe cell wall.
BETA-LACTAM INHIBITORS
• β-lactamasesare afamilyof enzymesproduced bymanygram-positive andgram-
negative bacteria thatinactivate β-lactamantibioticsbyopening the β-lactam
ring.
• Different β-lactamasesdiffer in their substrate affinities.
• Three inhibitors of this enzymeare Clavulanicacid,Sulbactamand Tazobactam
areavailablefor clinical use.
CLAVULANIC ACID
• Hasarapid oral absorption
• Additionof clavulanicacidre-establishes theactivityof amoxicillinagainst β-
lactamaseproducing resistant Staph.aureus (butnot MRSA), H. influenzae, N.
gonorrhoeae, E.coli,Proteus, Klebsiella, Salmonella and Shigella.
• Indicatedfor Respiratory tract,Skin& Softtissue, intra abdominalinfections.
• Dosage: 100mg/kg/dayin4 divided doses
SULBACTUM
• 2–3timesless potent thanclavulanicacid
• Oral absorptionofsulbactamis inconsistent.Therefore, it is preferably given
parenterally
• Ithasbeencombinedwith ampicillinfor useagainst β-lactamaseproducing
resistant strains
• UsedcommonlyinSurgicalInfections& Gonorrhea.
• DosageAmpicillinwithSulbactum: 200mg/kg/dayin4 divided doses
TAZOBACTUM
• Itis similar to sulbactam.
• Itspharmacokineticsmatcheswith piperacillin with whichit hasbeen combined
for use insevere infectionslike peritonitis, pelvic/urinary/respiratory infections
causedby β-lactamaseproducing bacilli.
• Dosage: Piperacillin+Tazobactum: 200-300mg/kg/dayin3 divided doses
THANKYOU

Beta lactamase inhibitors

  • 1.
    BETA-LACTAMASE INHIBITORS DR RAVI KUMARS PEDIATRIC RESIDENT MGMCRI
  • 2.
    BETA-LACTAM Antibiotics which containbeta lactam ringsin theirmolecular structuresare : • Penicillin • Cephalosporins • Monobactum • Carbapenem
  • 3.
    MOA • It interfereswithbacterial cell wall synthesis • It inhibitsthe transpeptidases so that cross linkingdoes not take place • Cross linkages between peptide chains of the neighbouringstrands provides stabilityand rigiditytothe cell wall.
  • 4.
    BETA-LACTAM INHIBITORS • β-lactamasesareafamilyof enzymesproduced bymanygram-positive andgram- negative bacteria thatinactivate β-lactamantibioticsbyopening the β-lactam ring. • Different β-lactamasesdiffer in their substrate affinities. • Three inhibitors of this enzymeare Clavulanicacid,Sulbactamand Tazobactam areavailablefor clinical use.
  • 5.
    CLAVULANIC ACID • Hasarapidoral absorption • Additionof clavulanicacidre-establishes theactivityof amoxicillinagainst β- lactamaseproducing resistant Staph.aureus (butnot MRSA), H. influenzae, N. gonorrhoeae, E.coli,Proteus, Klebsiella, Salmonella and Shigella. • Indicatedfor Respiratory tract,Skin& Softtissue, intra abdominalinfections. • Dosage: 100mg/kg/dayin4 divided doses
  • 6.
    SULBACTUM • 2–3timesless potentthanclavulanicacid • Oral absorptionofsulbactamis inconsistent.Therefore, it is preferably given parenterally • Ithasbeencombinedwith ampicillinfor useagainst β-lactamaseproducing resistant strains • UsedcommonlyinSurgicalInfections& Gonorrhea. • DosageAmpicillinwithSulbactum: 200mg/kg/dayin4 divided doses
  • 7.
    TAZOBACTUM • Itis similarto sulbactam. • Itspharmacokineticsmatcheswith piperacillin with whichit hasbeen combined for use insevere infectionslike peritonitis, pelvic/urinary/respiratory infections causedby β-lactamaseproducing bacilli. • Dosage: Piperacillin+Tazobactum: 200-300mg/kg/dayin3 divided doses
  • 8.

Editor's Notes

  • #6 that have altered PBPs